Abivax is a biotechnology company based in France, founded in 2013 and listed on the Paris Stock Exchange since 2015. Abivax mobilizes the body’s natural immune system machinery to treat patients with inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (ABX464), COVID-19 (ABX464), HIV (ABX464), and liver cancer (ABX196). Abivax’s mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Dr. Jorge Kalil Professor at FMUSP miR-AGE Trial National Coordinator CRM-SP 52834